Skip to main content
Formycon AG logo

Formycon AG — Investor Relations & Filings

Ticker · FYB ISIN · DE000A1EWVY8 LEI · 39120005TZ76GQOY8Z19 F Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2021-06-29 Regulatory Filings
Country DE Germany
Listing F FYB

About Formycon AG

https://www.formycon.com/en/

Formycon AG is an independent, globally operating biopharmaceutical company specializing in the development of high-quality biosimilars. As a pure-play biosimilar developer, the company focuses on creating follow-on products for complex biopharmaceutical medicines after their patent protection has expired. The core mission is to enhance patient access to safe, effective, and affordable biologic therapies. Formycon's development activities are concentrated in therapeutic areas with high medical need, including ophthalmology and immunology. The company manages the entire development process, from analytics and process development to clinical trials and regulatory approval submissions for its biosimilar candidates.

Recent filings

Filing Released Lang Actions
Formycon and Bioeq announce submission of the marketing authorization application for FYB201, a biosimilar candidate to Lucentis(R)1 (ranibizumab) to the European Medicines Agency (EMA)
Regulatory Filings Classification · 99% confidence The document is an 'Ad-hoc' announcement dated June 29, 2021, disclosing 'inside information' regarding the submission of a marketing authorization application (MAA) for a biosimilar candidate (FYB201) to the European Medicines Agency (EMA). This is a specific corporate action related to regulatory progress, not a comprehensive financial report (like 10-K or IR) or a general earnings release (ER). It is a regulatory/corporate update that doesn't fit the specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP). Since it is a specific announcement about a regulatory submission process, it is best classified as a general Regulatory Filing (RNS), which serves as the fallback for specific corporate news that doesn't match other defined categories, although it is highly specific news. Given the options, RNS is the most appropriate catch-all for this type of regulatory milestone announcement that isn't a formal financial report or a specific corporate event like M&A or a shareholder vote.
2021-06-29 English
Formycon announces conclusion of exclusive commercialization agreement between Bioeq AG and Teva Pharmaceutical Industries Ltd. for FYB201 in Europe, Canada, Israel and New Zealand
Regulatory Filings Classification · 99% confidence The document is an 'Ad-hoc' announcement dated June 28, 2021, disclosing an 'inside information acc. to Article 17 MAR'. The core content is the conclusion of an exclusive commercialization agreement between Bioeq AG and Teva Pharmaceutical Industries Ltd. regarding the biosimilar candidate FYB201. This type of announcement, detailing a significant business transaction (alliance/contract) and regulatory disclosure under MAR (Market Abuse Regulation), does not fit the specific definitions for financial reports (10-K, IR, ER), shareholder actions (AGM-R, DVA), or management changes (MANG). It is a general corporate news release concerning a strategic partnership. Since it is a specific corporate announcement that doesn't fit the other specialized categories, the most appropriate classification is the general regulatory announcement fallback, RNS (Regulatory Filings), as it is explicitly labeled as an 'Ad-hoc' disclosure transmitted via DGAP, a service for regulatory announcements.
2021-06-28 English
Formycon Publishes Annual Financial Statements for the 2020 Financial Year
Earnings Release Classification · 100% confidence The document is titled "Formycon Publishes Annual Financial Statements for the 2020 Financial Year" and contains key financial highlights (turnover, EBITDA, EBIT, annual result) for the full 2020 financial year. It explicitly mentions the publication of the 'Annual Financial Statements' and provides a link to the 'full 2020 annual financial statements / annual report'. Although it contains summary data typical of an Earnings Release (ER), the focus on the *full year* results and the explicit reference to the 'Annual Report' strongly suggests this is the announcement accompanying the official annual filing. Since the document length is substantial (9729 chars) and it contains detailed financial figures, it is more than just a brief announcement (RPA). However, it is an announcement *of* the Annual Financial Statements, not the full 10-K document itself. In many contexts, the press release summarizing the full annual results is classified as an Earnings Release (ER) or sometimes an Interim Report (IR) if it were quarterly. Given the context of 'Annual Financial Statements for the 2020 Financial Year' and the presence of detailed financial metrics, it aligns best with the initial release of annual results, which is the Earnings Release (ER) category, even though the full 10-K document is the comprehensive filing. If the document *was* the 10-K, it would be classified as 10-K. Since this is the press release summarizing the annual performance, ER is the most appropriate fit among the provided options, as it precedes or accompanies the formal 10-K filing. FY 2020
2021-05-17 English
Annual financial statements 2020
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2020' for Formycon AG. It contains a 'Letter to Shareholders', 'Management Report', 'Consolidated Financial Statements', and 'Report of the Supervisory Board'. It is a comprehensive yearly report covering company activity and financial performance, which fits the definition of a 10-K (Annual Report). FY 2020
2021-05-17 German
Formycon receives approval for early action for COVID-19 drug FYB207 as part of a grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy (StMWi)
Regulatory Filings Classification · 100% confidence The document is a press release dated April 27, 2021, announcing that Formycon AG received approval for early action for a grant from the Bavarian Ministry of Economic Affairs to fund the development of its COVID-19 drug FYB207. This announcement details financing/funding related to a development project, including the requested amount (approx. Euro 11 million) and the scope (Phase IIa clinical trials). This content aligns best with the 'Capital/Financing Update' category, as it is a significant announcement regarding securing public funding for corporate development activities. It is not a full financial report (10-K or IR), an earnings release (ER), or a management discussion (MDA).
2021-04-27 English
Formycon's COVID-19 Drug FYB207 even more efficient against SARS-CoV-2 Mutant B.1.1.7
Regulatory Filings Classification · 99% confidence The document is explicitly labeled as a 'Press Release' and contains 'News Details' disseminated via 'DGAP-News'. The content focuses on announcing new scientific study results regarding Formycon's drug FYB207 against a COVID-19 mutant. This is a typical structure for an immediate public announcement of operational or scientific progress, rather than a comprehensive periodic financial report (like 10-K or IR) or a formal regulatory filing like a proxy statement or insider trade report. Since it is an announcement of scientific/operational news, and not a formal financial report, the most fitting category is 'Earnings Release' (ER) if it were financial results, but since it is scientific/operational news, and not a general regulatory filing (RNS), we must check other options. It is not a Call Transcript (CT), Audit Report (AR), or Management Discussion (MDA). Given the context of a press release announcing key operational/scientific updates, 'ER' (Earnings Release) is often used broadly for initial results announcements, but 'RNS' (Regulatory Filings) serves as the best general category for non-standard, immediate corporate news releases that don't fit the specific financial/governance codes. However, since the content is a scientific update, and not a financial earnings summary, and it is not a formal regulatory form, 'RNS' is the appropriate fallback for this type of corporate news release.
2021-03-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.